INmune Bio's XPro™ Shows Promising Phase 2 Results in Alzheimer’s Trial
Event summary
- INmune Bio published Phase 2 MINDFuL trial results in NPJ Dementia on May 15, 2026, showing directional cognitive and biomarker improvements in an inflammation-enriched Alzheimer’s subgroup.
- XPro™ demonstrated effect sizes up to 0.27 across cognitive, functional, and behavioral endpoints with no ARIA observed.
- The trial targeted an enriched population (n=100) with amyloid-beta positivity and inflammation biomarkers, supporting a biomarker-driven strategy for future studies.
- FDA Fast Track designation for XPro™ strengthens the platform’s value in inflammation-driven diseases.
The big picture
INmune Bio’s Phase 2 results position XPro™ as a potential differentiated therapy for Alzheimer’s disease with inflammation, a growing focus area in neuroscience. The biomarker-enriched approach aligns with broader industry trends toward precision medicine in neurodegenerative disorders. The FDA Fast Track designation adds regulatory momentum, but the path to commercialization will depend on confirming efficacy in larger trials.
What we're watching
- Clinical Validation
- Whether the Phase 2 signal in the inflammation-enriched subgroup can be replicated in larger, Phase 3 trials.
- Regulatory Strategy
- How the FDA Fast Track designation will shape the path to approval for XPro™ in Alzheimer’s disease.
- Biomarker Enrichment
- The pace at which INmune Bio can refine its biomarker strategy to optimize future trial designs.
Related topics